
Pharmacally
pelareorep
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in pelareorep
Clinical TrialsOncolytics Reports Promising Survival Data With Pelareorep CombinationOncolytics Biotech reported an approximately 15-month median duration of response with pelareorep plus atezolizumab in previously treated squamous cell anal cancer.Fact-Checked
Health TidingsFDA Grants Fast Track Designation to Oncolytics’s PelareorepThe FDA has granted Fast Track designation to Oncolytics Biotech’s pelareorep plus a checkpoint inhibitor for advanced squamous cell carcinoma of the anal canal (SCAC) after progression on…Fact-Checked
Health TidingsOncolytics Biotech Aligns with FDA on Pivotal Trial Design for Pelareorep in Anal CancerOncolytics Biotech Inc. has reached agreement with the U.S. Food and Drug Administration on a randomized controlled trial design to evaluate pelareorep in advanced anal cancer, with the…Fact-Checked
Health TidingsOncolytics to Discuss Pivotal Pelareorep Study in Late-Line Anal Cancer with FDAOncolytics announced a Type C FDA meeting to discuss a potential registrational pathway for pelareorep in squamous cell anal carcinoma.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.